Cargando…
Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism
• COVID-19 pneumonia could be associated with an increased risk of venous thrombosis. • Antiphospholipid antibodies might be involved in thrombosis in COVID-19 patients. • Prevalence of antiphospholipid antibodies in COVID-19 and venous thrombosis was low.
Autores principales: | Galeano-Valle, F., Oblitas, C.M., Ferreiro-Mazón, M.M., Alonso-Muñoz, J., del Toro-Cervera, J., di Natale, M., Demelo-Rodríguez, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227496/ https://www.ncbi.nlm.nih.gov/pubmed/32425261 http://dx.doi.org/10.1016/j.thromres.2020.05.017 |
Ejemplares similares
-
Omalizumab as a Provoking Factor for Venous Thromboembolism
por: Oblitas, Crhistian-Mario, et al.
Publicado: (2019) -
Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review
por: Galeano-Valle, Francisco, et al.
Publicado: (2021) -
Risk of thrombosis recurrence among patients with COVID-19 and surgery-associated venous thromboembolism
por: Alonso-Beato, R., et al.
Publicado: (2023) -
Rivaroxaban for the treatment of venous thromboembolism in real life: A single-center prospective study
por: Demelo-Rodríguez, Pablo, et al.
Publicado: (2019) -
COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding
por: Demelo-Rodriguez, Pablo, et al.
Publicado: (2023)